These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Dose-effect relationships of prostaglandin E1 in severe endstage chronic heart failure.
    Author: Stanek B, Pacher R.
    Journal: Jpn Heart J; 1997 Jan; 38(1):53-65. PubMed ID: 9186281.
    Abstract:
    UNLABELLED: Prostaglandin E1 is a potent vasodilator in severe chronic heart failure. To evaluate the time sequence and magnitude of prostaglandin E1's hemodynamic effects a dose finding study was performed in 24 patients. Right heart catheterization was performed and prostaglandin E1 was administered via a central venous line in incremental doses of 2.5, 10, 20, 30 and 40 ng/kg/min, each dose, lasting 15 min before hemodynamic evaluation. The first significant change was a approximately 20% decrease in systemic vascular resistance index accompanied by a approximately 18% increase in cardiac index at an infusion rate of 2.5 ng/kg/min of prostaglandin E1, which was sustained at 5 ng/kg/min in all patients. A dose response-curve with cumulative doses ranging from 2.5 to 25 ng/kg/min of prostaglandin E1 was established in a subset of 14 patients due to 10 drop-outs at lower dosages. At 2.5 and 5 ng/kg/min of prostaglandin E1, cardiac index increased by 18% (p < 0.05) and peripheral resistance decreased by 18% (p < 0.01). These changes were sustained up to a maximal dose of 25 ng/kg/min, which was tolerated by all patients in this group. At 15 and 20 ng/kg/min of prostaglandin E1 a significant decrease in blood pressure of -4 mmHg (p < 0.05) was observed which was reversed at the next dose step. In a second analysis maximal tolerated dosages of prostaglandin E1 were evaluated in all 24 patients (group A, 26 +/- 2 ng/kg/min), and in two subsets using a maximum tolerated dose of 20 ng/kg/min as a cutpoint (B: 14 patients, 34 +/- 2 ng/kg/min; C: 10 patients, 15 +/- 2 ng/kg/min) Then the respective peak dosages were halved for continuous infusion through 12 hours. In the acute study pulmonary capillary wedge pressure (by A: -11%, p < 0.01; B: -4%, p < 0.01; C: -22%, p < 0.01) and systemic vascular resistance (by A: -32%, p < 0.0001; B: -25%, p < 0.001; C: -43%, p < 0.001) decreased significantly in all three groups and cardiac index increased (by A: +38%, p < 0.0001; B: +33%, p < 0.0001; C: +59%, p < 0.0001). In the chronic study these changes were sustained. Furthermore, mean arterial pressure (by A: -14%, p < 0.0001; B: -13%, p < 0.001; C: -13%, p < 0.05), right atrial pressure (by A: -36%, p < 0.0001; B: -36%, p < 0.01; C: -30%, p < 0.01), pulmonary artery pressure (by A: -16%, p < 0.0001; B: -16%, p < 0.01; C: -19%, p < 0.01) and pulmonary vascular resistance (by A: -28%, p < 0.01; B: -31%, p < 0.01; C: -25%, p < 0.01) were significantly reduced after 12 hours. CONCLUSION: These results demonstrate potent hemodynamic effects of low-dose prostaglandin E1 in severe heart failure. While systemic effects appear rapidly, a slow onset of the pulmonary effects was observed.
    [Abstract] [Full Text] [Related] [New Search]